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Ehrlichiae are small, gram-negative, obligately intracellular bacteria that reside within a
phagosome. The first human ehrlichial infection was recognized in the United States in 1987.
It was later shown to be caused by a new species, Ehrlichia chaffeensis. In 1994, an
ehrlichial pathogen within neutrophils that is closely related to the known veterinary patho-
gens E. equi and E. phagocytophila was found to infect humans. Molecular methods were
required to detect, characterize, and identify these fastidious and uncultivated bacteria.
Subsequently, E. chaffeensis infection was documented in more than 400 patients in 30
states, Europe, and Africa. Likewise, approximately 170 cases of human granulocytic
ehrlichiosis have been diagnosed, most since 1994, predominantly in the upper midwestern
and northeastern states, but also in northern California. The disease caused by ehrlichiae
is generally undifferentiated but is often associated with leukopenia, thrombocytopenia, and
elevated serum hepatic transaminase levels in tick-exposed patients. Infection ranges from
subclinical to fatal; tetracycline appears to be an effective therapy. The emergence of these
two newly recognized tickborne infections as threats to human health is probably due to
increased clinical cognizance, but as in other emerging tickborne infections, it is likely that
the rapid increase in identified cases signals a true emergence of disease associated with
a changing vector-host ecology.
During the last decade, two previously un-
known human diseases caused by Ehrlichia spe-
cies have emerged as public health problems in the
United States. Each of these infectious diseases is
designated by the major target cell: human mono-
cytic ehrlichiosis is caused by Ehrlichia chaffeen-
sis, and human granulocytic ehrlichiosis by an E.
equi-like organism. The taxonomic positions of
these bacteria have been determined with much
greater scientific clarity by the recent application
of molecular methods, which were critical for the
identification of E. chaffeensis and essential for
that of human granulocytic ehrlichia (HGE) (1,2).
Extreme difficulty in developing methods for cul-
tivation of these ehrlichiae and, until recently, the
lack of molecular approaches to the study of un-
cultivated organisms partly explain why these far
from rare diseases were not detected sooner (3-5).
However, it was the observation of Romanowsky-
stained blood smears by classic microscopy that
actually opened the door to the discovery of both
diseases (6,7). This article reviews ehrlichiae and
describes their taxonomic and ecologic niches
within the scheme of bacterial evolution and the
substantial knowledge, developed largely by the
veterinary sciences, that served as a foundation
for the discovery and elucidation of the human
ehrlichioses.
Evolution of Ehrlichiae in Unusual Ecologic Niches
Among the obligately intracellular gram-nega-
tive bacteria, a genetically related set is classified
among the Protobacteria of the a subgroup on the
basis of sequence analysis of the 16S rRNA gene
(1,2,8,9). The overview of the evolution of these
organisms provided by this approach lacks many
details essential to the understanding of human
disease; however, the evolution of these organisms
correlates well with the clonal divergence of many
species that do not have opportunities for genetic
recombination because of their intracellular isola-
tion from other organisms. These bacteria have
evolved in close association with ticks, mites, chig-
gers, fleas, other arthropods, and fish flukes into
six genetically defined clusters (1,2,8-11) (Table 1
and Figure 1). Future definition of the details
determined by many other important genes may
designate these six clusters as separate taxonomic
genera. Currently, however, the presence of organ-
isms named as Ehrlichia species within three of
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other genus names also fall into each of the clus-
ters (Tables 1 and 2).
Historical Foundations for Recognizing the Human
Ehrlichioses in the United States
The current, albeit incomplete, knowledge of
the human ehrlichioses has a long history. The
emergence of ehrlichiae began in 1910, when
Theiler described Anaplasma marginale, the
etiologic agent of an economically important, se-
vere worldwide disease of cattle. The contribu-
tions of veterinary medical science to the
understanding of ehrlichiae have continued ever
since; they include the description of Cowdria
ruminantium by Cowdry in 1925, of E. canis by
Donatien and Lestoquard in 1935, and E. phago-
cytophila by Gordon in 1940. The genus Ehrlichia
was established in 1945 in honor of the German
microbiologist Paul Ehrlich, and the general sci-
entific distinction of rickettsiae and ehrlichiae
from viruses and protozoa followed soon thereaf-
ter, mainly as a result of the advent of antibiotics
and electron microscopy. Molecular methods are
now used to identify various species. Indeed, E.
sennetsu, the etiologic agent of a human infectious
mononucleosis-like illness described in Japan in
1954, was considered a Rickettsia for many years.
Numerous veterinary discoveries preceded the
recognition of human ehrlichial infections in the
United States: Neorickettsia helminthoeca in
1950,  N. elokominica in 1964, E. equi in 1969, E.
ewingii in 1971, E. platys in 1978, and E. risticii
in 1984 (12). Substantial emphasis on the study of
ehrlichiae was stimulated by a disastrous epizo-
otic of canine ehrlichiosis that resulted in 200 to
300 deaths among military working dogs in Viet-
nam from 1968 until 1970. After the discovery, in
1984, that the etiologic agent of Potomac horse
fever was a novel species designated as E. risticii,
Table 1. Six related clusters of obligately intracellular
gram-negative bacteria determined by 16S rRNA
comparisons
Prototype species Other genera within Vector
of the cluster genetic confines relationship   
I. Ehrlichia canis Cowdria Ticks
II. E. phagocytophila Anaplasma Ticks
III. E. sennetsu Neorickettsia Fish flukes
IV. Wolbachia pipientis Rhinocyllus, Nasonia Insects
incompatibility intra-
cellular symbionts
V. Rickettsia rickettsii None Ticks, fleas,
Mites, lice
VI. Orientia tsutsuga- None Chiggers
mushi * (R. 
tsutsugamushii)
* Proposed new taxonomic designation (20).
Figure 1. Dendrogram
representing the phylo-
genic relationships of
ehrlichiae and other Pro-
tobacteria as determined
by 16S rDNA sequence
similarity. The three clus-
ters of bacteria enclosed
in rectangles include or-
ganisms designated as
Ehrlichia, although they
differ substantially.
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ehrlichiae have been achieved, particularly in the
laboratory of Yasuko Rikihisa at the Ohio State
University College of Veterinary Medicine. In-
deed, blinded to the potential relevance of Ehr-
lichia ssp. to human medicine, we missed
numerous opportunities during the 1980s to in-
vestigate canine ehrlichiosis.
Emergence of Human Monocytic Ehrlichiosis 
A single, somewhat unusual case in 1986 led to
the recognition of human ehrlichial infections in
the United States (6). A 51-year-old man who had
been bitten by a tick in Arkansas and had been
sick for 5 days was admitted to a hospital in
Detroit. He was critically ill with fever, headache,
myalgia, confusion, azotemia, hypoxemia, and
thrombocytopenia and had cytoplasmic inclusions
in his peripheral blood leukocytes. Peripheral
blood smears and electron micrographs of the in-
clusion-bearing leukocytes examined at the Cen-
ters for Disease Control (CDC) suggested that the
organisms were an Ehrlichia sp. Serologic evalu-
ation showed a high titer of antibodies reactive
with E. canis that fell sharply during convales-
cence. The patient had a prolonged hospitalization
complicated by renal failure which required
hemodialysis; upper gastrointestinal hemor-
rhage; severe central nervous system involve-
ment; and systemic Candida infection.
State public health agencies and CDC demon-
strated that many patients originally suspected to
have Rocky Mountain spotted fever or another
rickettsiosis (13) produced antibody to E. canis, a
canine pathogen. In Oklahoma, the state with the
highest incidence of Rocky Mountain spotted fe-
ver, serologic evidence suggested that human
monocytic ehrlichiosis occurred at the same inci-
dence as Rocky Mountain spotted fever (14). In a
Table 2. Three related clusters of bacteria-containing species designated as Ehrlichia
Vertebrate host Transmission Major target cell
Genogroup I
Ehrlichia canis Canids Rhipicephalus sanguineus Monocyte/macrophage
   tick bite
E. chaffeensis Humans, deer Amblyomma americanum Monocyte/macrophage
 tick  bite
E. ewingii Canids A. americanum tick bite Polymorphonuclear
 leukocytes
E. muris Vole Unknown Monocyte/macrophage
Cowdria ruminantium Cattle, sheep, goats,  Amblyomma spp. tick bite Endothelium
 antelope,
 African  buffalo
Genogroup II
E. equi Horses Ixodes spp. tick bite Neutrophils
E. phagocytophila Sheep, cattle, deer Ixodes ricinus tick bite  Neutrophils
Human granulocytic Humans, deer,  I. scapularis (dammini) Neutrophils
 ehrlichia  rodents  (?)  tick  bite
E. platys Canids Unknown Platelets
Anaplasma marginale Cattle Boophilus, Rhipicephalus, Erythrocytes
  and other tick bites
Genogroup III
E. sennetsu Humans Possibly ingestion of raw Monocyte/macrophage
   fish
E. risticii Horses Unknown Monocytes, enterocytes,
 mast  cells
Neorickettsia helminthoeca  Canids Salmon fluke ingestion Macrophage
N. elokominica Canids Salmon fluke ingestion Macrophage
Stellantchasmus falcatus None known Grey mullet fluke Unknown
   (SF) agent
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hospitalized patients in southeastern Georgia,
ehrlichial disease was sixfold more prevalent than
Rocky Mountain spotted fever and was associated
with history of tick bite, anorexia, chills, weight
loss, sweating, headache, nausea, myalgia, throm-
bocytopenia, and elevated serum concentrations of
hepatic transaminases in 50% or more of the pa-
tients and by arthralgia, vomiting, diarrhea, ab-
dominal pain, cough, rash, and leukopenia in
fewer than half of the patients (15). Mild and
asymptomatic seroconversion to ehrlichial
antigens has also been associated with tick expo-
sure (16).
A  practical method for the cultivation of E.
canis (the suspected cause of human ehrlichial
infections), developed at CDC, used the cultivated
organisms to establish a reliable indirect im-
munofluorescence assay (IFA) for the diagnostic
demonstration of antibodies in serum (17). In ret-
rospect, it is apparent that E. canis was a rela-
tively sensitive surrogate antigen because it
shares some, but by no means all, of the antigens
of the etiologic Ehrlichia. The method of ehrlichial
cultivation in a continuous canine histiocytoma
cell line (DH82) was also successfully applied to
the isolation of an Ehrlichia species from the blood
of a febrile soldier at Fort Chaffee, Arkansas (3).
Molecular methods were also applied to establish,
on the basis of the DNA sequence of the 16S rRNA
gene, that E. chaffeensis is a novel species (1).
Current Knowledge of E. chaffeensis and Human
Monocytic Ehrlichiosis
Microbiology of the Etiologic Agent
Ultrastructural investigation of E. chaffeensis
demonstrated that the inner and outer leaflets of
the cell wall were equal in thickness. Rickettsia
species have a thinner outer leaflet and thicker
inner leaflet, and Orientia (Rickettsia) tsutsuga-
mushi has a thicker outer leaflet and thinner inner
leaflet (18-20) (Figures 2 and 3). Two distinct
morphologic forms, larger reticulate cells with
uniformly dispersed nucleoid filaments and ribo-
somes and smaller cells with central condensation
of nucleoid filaments and ribosomes, were ob-
served undergoing binary fission, evidence
against a developmental cycle (Figure 3). Many
forms were observed, including numerous intra-
morular vesicles and tubules originating from the
ehrlichial cell wall and fibrillar material
consisting of ehrlichial antigen. Abnormal forms
included giant and multilobar ehrlichiae.
Western immunoblot technique has detected
seven major proteins: 120, 66, 58, 44, 29, 28, and
22 kDa; the greatest number of antigens are
shared with E. canis (21). Monoclonal antibodies
and monospecific polyclonal antibodies demon-
strated that the major, immunodominant 120-,
29-, 28-, and 22-kDa proteins (as well as a minor
30-kDa protein) are surface-exposed and that the
28- and 22-kDa proteins are related antigenically.
Further human isolations of ehrlichiae have
shown antigenic and genetic diversity among
strains of E. chaffeensis (4).
DNA cloning has shown that 58- and 10-kDa
proteins are genetically homologous to the
Figure 2. Human granulocytic ehrlichiae (BDS strain)
in an equine peripheral blood neutrophil are located
within four morulae. Reticulate (r) and dense-cored (d)
cells are surrounded by two membranes: cell wall mem-
brane and cytoplasmic membrane. Bar = 1 mm; magni-
fication,  x 27,000. (Courtesy of Vsevolod Popov,
University of Texas Medical Branch at Galveston.)
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proteins (22). The 120-kDa protein includes a re-
gion of identical 80 amino acid tandem repeat
units, and preliminary evidence suggests that it
mediates adhesion to the host cell. Establishment
and study of tick isolates and identification of
virulence factors are clearly important aims for
future research.
Clinical Manifestations
Most cases of human ehrlichiosis have been
diagnosed after a moderate-to-severe illness (23).
Some patients have a life-threatening illness
resembling toxic shock syndrome (24). Deaths
have occurred in approximately 2% to 3% of pa-
tients, including previously healthy children
(13,23-28). Among 237 cases between 1985 and
1990 investigated by CDC, 62% of patients were
hospitalized (23). The median duration of illness,
including that for treated patients, was 23 days.
The signs and symptoms depict a systemic disease
that has no clinically diagnostic features: fever
(97%), headache (81%), myalgia (68%), anorexia
(66%), nausea (48%), vomiting (37%), rash (6% at
onset, 25% during the first week, and 36% overall),
cough (26%), pharyngitis (26%), diarrhea (25%),
lymphadenopathy (25%), abdominal pain (22%),
and confusion (20%). Severe complications include
respiratory and renal insufficiency and serious
neurologic involvement. Of patients with chest
radiographic examinations, nearly half have pul-
monary infiltrates (13). Clinical laboratory find-
ings include leukopenia (60%), thrombocytopenia
(68%), and elevated hepatic transaminases (86%).
Hepatic involvement has been described as severe
in individual cases (29). Central nervous system
involvement has been documented by the occur-
rence of seizures, coma, and cerebral lesions at
autopsy as well as by cerebrospinal fluid (CSF)
pleocytosis, increased CSF protein concentration,
and the presence of E. chaffeensis in CSF demon-
strated by immunocytology and polymerase chain
reaction (PCR) (24,30,31). Recognition of serious
myocardial involvement further emphasizes the
potential gravity of this disease and the incom-
pleteness of our knowledge of its clinical manifes-
tations (32). Seroconversion to E. chaffeensis
among 1.3% of 1,187 soldiers during training ex-
ercises with tick exposures suggests that human
risk for infection with it or an antigenically related
Ehrlichia is relatively high (16). However, the fact
that two-thirds of the seroconverters remained
asymptomatic emphasizes that the relationship
between severity of illness and either host factors
or ehrlichial strain differences in virulence re-
mains unknown.
Epidemiology of Human Monocytic Ehrlichiosis and
Ecology of E. chaffeensis
More than 400 cases of serologically confirmed
E. chaffeensis infection have been documented at
CDC, which has one of the few laboratories capa-
ble of performing diagnostic ehrlichial serology.
That these cases most likely represent but the tip
of the iceberg was confirmed when inquiry at MRL
Diagnostics, a commercial reference laboratory
that offers IFA serology for E. chaffeensis, reported
722 positive specimens between September 1992
Figure 3. Human monocytic ehrlichiae (Ehrlichia
chaffeensis, Sapulpa strain) in host-cell mem-
brane-limited parasitophorous vacuoles (morulae)
of a DH82 cell (canine macrophage cell line). Ehr-
lichial reticulate cells (r) are limited by two mem-
branes. The outer one—the cell wall membrane—is
usually wavy (arrowheads). One Ehrlichia is divid-
ing by binary fission (arrow). Bar = 1 mm; magnifi-
cation, x 18,000. (Courtesy of Vsevolod Popov,
University of Texas Medical Branch at Galveston.)
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required or otherwise, for notifying public health
authorities of cases. Relatively few physicians
even know that these diseases exist and, thus,
most of them are not making the diagnosis. Even
highly knowledgeable physicians find ehrlichiosis
virtually impossible to diagnose on the basis of
clinical signs and symptoms. Most patients (83%)
report exposure to ticks or tick bite within the 3
weeks of onset of illness (13,23). Cases are pre-
dominantly rural (66%) and seasonal (68% during
May-July). The median age of patients is 44 years,
and three-quarters are male. Outbreaks of human
monocytic ehrlichiosis among groups of golfers
and campers emphasize the risk for infection dur-
ing outdoor activities with tick exposure (16,33).
Human monocytic ehrlichiosis occurs not only as
an acute illness of apparently immunocompetent
persons but also as an opportunistic infection of
patients with compromised host defenses, includ-
ing acquired immunodeficiency syndrome (AIDS)
patients (24,26). The report of a fatal E. chaffeensis
infection in an AIDS patient, in whom a diagnostic
antibody response to E. chaffeensis never devel-
oped, suggests that such cases would not usually
be diagnosed correctly.
E. chaffeensis has been detected in two tick
species, Amblyomma americanum (the lone star
tick) and Dermacentor variabilis (34,35) (the
American dog tick). Human monocytic ehrlichiosis
has been confirmed in 30 states. Most cases have
occurred within the range of A. americanum, and
a high proportion of the remainder have occurred
within the range of D. variabilis. Ehrlichiae have
been detected specifically by PCR in adult (but not
in nymphs) A. americanum ticks in Missouri,
North Carolina, Kentucky, and New Jersey; a sin-
gle E. chaffeensis PCR-positive D. variabilis  tick
was found in Arkansas. On the other hand, cases
reported in Wyoming, Utah, Washington, Europe,
and Africa suggest the possibility of additional
vectors (23,36,37) or other antigenically related
ehrlichial organisms.
White-tailed deer (Odocoileus virginianus) in
Alabama, Arkansas, Florida, Georgia, Illinois,
Kentucky, Louisiana, Maryland, Mississippi, Mis-
souri, North Carolina, South Carolina, Tennessee,
Texas, and Virginia have antibodies reactive with
E. chaffeensis. These deer are susceptible to ex-
perimental infection with ehrlichiae that can cir-
culate for weeks (38,39). The close association
among  E. chaffeensis, the lone star tick, and white-
tailed deer was vividly illustrated by the
sequential appearance of A. americanum ticks and
antibodies to E. chaffeensis in a population of deer
in Georgia (40). The prevalence of lone star ticks
and seropositivity both rose from 1983 to 1990
when 100% of deer examined were infested with
A. americanum and had serum antibodies to E.
chaffeensis. The possibility that the immature
ticks acquired the ehrlichiae from another mam-
malian host, such as a small rodent, before it was
transmitted to deer cannot be excluded. Experi-
mentally infected dogs have ehrlichemia for at
least 26 days and, thus, could also serve as a
reservoir host (41). Related ehrlichioses for which
the ecology and transmission are known are main-
tained in a cycle involving a mammalian host and
a tick vector (12). For example, Rhipicephalus
sanguineus ticks acquire E. canis infection when
feeding on infected dogs as larvae or nymphs
(42,43). Although the ticks remain infected as they
molt from stage to stage, transovarian transmis-
sion does not occur. It seems likely that deer, dogs,
or small rodents serve as the reservoir hosts for E.
chaffeensis, and that A.americanum ticks serve as
the major vector. Indeed, larval and nymphal A.
americanum acquire E. chaffeensis by feeding on
infected deer, maintain the ehrlichiae trans-
stadially, and transmit E. chaffeensis while feed-
ing as nymphs and adults on naive deer (44).
Diagnosis and Treatment
The diagnosis of human monocytic ehrlichiosis
is usually difficult to establish during the acute
stage of the infection, even in severe cases.
Ehrlichiosis should be considered in any febrile
patient who has been exposed to ticks during the
previous 3 weeks, particularly if leukopenia and
thrombocytopenia are present.
Most cases have been confirmed by a humoral
immune response generating antibodies reactive
with E. chaffeensis or the surrogate antigen, E.
canis (17,23). Use of E. chaffeensis antigens for IFA
serology results in greater diagnostic sensitivity
than use of E. canis antigens (3). Diagnostic rises
in antibody titer usually occur by the third week
after onset, and a precipitous decline in antibody
occurs in most patients during the following year.
A fourfold rise or fall in IFA titer with a peak titer
of 64 or greater is considered diagnostic in a clini-
cally compatible case. Only two cases have been
documented by ehrlichial isolation (3,4), approxi-
mately 30 cases by E. chaffeensis-specific PCR
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histology or immunocytology (25-28,30,46). Fur-
thermore, antibodies to E. chaffeensis did not de-
velop in six PCR-confirmed patients during
convalescence, suggesting that serologic testing
may be less sensitive than generally assumed
(31,45). The sensitivity of PCR seems to be 80% to
87%; the specificity depends critically upon avoid-
ing contamination with ehrlichial DNA. Search for
morulae of E. chaffeensis in leukocytes is unre-
warding. Even an exhaustive search of buffy coat
smears seldom yields a diagnostic result.
Retrospective analysis showed that treatment
with tetracycline was associated with reduced
need for hospitalization of patients and with the
shortest median duration of treatment to effect
defervescence for hospitalized patients (2 days as
compared with 3 days for chloramphenicol and 7
days for all other antibiotics) (23).  E. chaffeensis
is killed in cell culture in the presence of doxycy-
cline or rifampin but is resistant to chlorampheni-
col, ciprofloxacin, erythromycin, cotrimoxazole
gentamicin, and penicillin (47). E. chaffeensis can
establish persistent infection even after treatment
with tetracycline and chloramphenicol (25). Per-
sistent ehrlichial infection, in some instances even
after treatment, is a well-documented aspect of
the veterinary ehrlichioses, e.g., canine monocytic
ehrlichiosis (E. canis) and tick-borne fever (E.
phagocytophila). The long-term implications of
persistent ehrlichiosis in humans are unclear but
might include subsequent reactivation of infection
or altered host defenses.
Pathology, Pathogenesis, and Immunity
E. chaffeensis is introduced into the dermis by
the bite of an infected tick and spreads hemato-
genously throughout the body. Intracellular infec-
tion is established within phagosomes, most often
in macrophages in the spleen, liver, lymph nodes,
bone marrow, lung, kidney, and cerebrospinal fluid
(25-28,30,46). Lesions potentially attributable to
ehrlichial infection include focal necroses of the
liver, spleen, and lymph nodes; multiorgan peri-
vascular lymphohistocytic infiltrates; hemo-
phagocytosis in the spleen, liver, lymph nodes, and
bone marrow; interstitial pneumonitis; and pul-
monary hemorrhage. In bone marrow specimens
from 12 patients, the most important findings
related to the hematopoietic response were
myeloid hyperplasia (8 cases), myeloid hypoplasia
(1 case), pancellular hypoplasia (1 case), and
megakaryocytosis (7 cases) (46). The most striking
discovery was the frequent occurrence of granu-
lomas (in 8 cases) and marrow histiocytosis (in 1
case) as manifestations of the reaction of macro-
phages to this organism.
The pathogenic mechanisms of ehrlichial dis-
ease are poorly understood. E. chaffeensis directly
causes necrosis of heavily infected cells in vitro
and in immunocompromised patients (7,26);
however; the role of host immune and inflamma-
tory responses as disease mechanisms has yet to
be determined. Observations of opportunistic fungal
and viral infections in severe and fatal cases sug-
gest the possibility of an ehrlichial role in the
suppression or dysregulation of the immune re-
sponse (6,25).
It is quite likely that E. chaffeensis is controlled
by a combination of cell-mediated and humoral
immune mechanisms. Interferon-activated hu-
man monocytes kill E. chaffeensis in vitro. The
ehrlichicidal activity is reversed by holotransfer-
rin, suggesting that E. chaffeensis is inhibited by
intracellular iron depletion (48). The closely re-
lated E. canis organisms, which grow in canine
macrophages in the presence of normal canine
serum and cause macrophage necrosis, are killed
by canine macrophages when the ehrlichiae are
opsonized by immune serum (49,50). Among pa-
tients who are treated successfully with an
anti-ehrlichial drug, the disease-associated lym-
phocytopenia is corrected and within 2 to 3 days
lymphocytosis develops (51). The predominant
(range, 41% to 97%) lymphocyte population
comprises g/d T lymphocytes, cells that usually
constitute only 3% to 8% of peripheral lympho-
cytes at the institution where the patients were
studied. The function of these cells in this setting
is unclear as are the consequences of the low a/b
T-lymphocyte concentration.
Emergence of Human Granulocytic Ehrlichiosis
Human granulocytic ehrlichiosis was recog-
nized originally in Duluth, Minnesota, by Johan
Bakken as a clinical syndrome of a potentially
fatal febrile illness in which the patient’s neutro-
phils contained cytoplasmic inclusions (7). Upon
reading an update on human ehrlichioses at the
time of the index case, which had a dramatic fatal
course, Bakken hypothesized that the infection
might have been ehrlichiosis. Collaboration with
the authors, who were working together at the
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resulted in the evaluation of a series of patients
who were suspected by Bakken to have the dis-
ease. Cytoplasmic inclusions were observed in
neutrophils, which differed from the findings in E.
chaffeensis infections, in which the mono-
cyte/macrophage is the principal target cell and
the detection of circulating leukocytes with inclu-
sions is a rare event. Moreover, IFA tests for
antibodies to E. chaffeensis performed in the
Texas laboratory and subsequently in Dumler’s
laboratory at the University of Maryland were
uniformly negative (4).
In retrospect, June 18, 1992, was a significant
day in the history of human granulocytic
ehrlichiosis. It was Dumler’s last day as a fellow
in Galveston before moving to Baltimore to be-
come an assistant professor and establish his own
independent ehrlichial research laboratory, and it
was Sheng-min Chen’s first day as a fellow. Mo-
mentously, the blood of a 78-year-old Wisconsin
man was collected and sent to Galveston by Bak-
ken on the same day. Culture for ehrlichiae and
acute- and convalescent-phase serologic assays for
E. chaffeensis, E. canis, E. sennetsu, and E. risticii
were all negative. PCR amplification of the 16S
rDNA, the approach developed by Wilson (52) and
applied by Relman and co-workers to identify the
etiologic agent of bacillary angiomatosis (53), was
performed successfully on the specimen by Chen
3 months later (2). Sequencing the gene was not a
high priority compared with pursuit of the re-
search aims of funded projects during the season
when the ticks were expected to be less active. By
April of 1993, DNA sequencing of half the 16S
rDNA had been accomplished, and it was recog-
nized that the organism was most closely related
to E. phagocytophila and E. equi, closely related to
E. platys, less closely related to E. chaffeensis, and
distantly related to E. sennetsu. Completion and
repeated confirmation of sequencing of both sense
and antisense strands enabled genogroup-specific
primers to be designed for nested PCR in July
1993.
What had progressed as a collaborative project
became the major project in Dumler’s laboratory
as Chen and Walker refocused their efforts on
funded E. chaffeensis research. The initial joint
publications with Bakken documented 12 cases
diagnosed by specific PCR and the identification
of morulae in circulating neutrophils (7). Two
patients had died. Necropsy performed on one
patient showed ultrastructurally and
immunohistologically identified ehrlichiae in neu-
trophil phagosomes in the spleen. Convalescent-
phase IFA serology with surrogate antigens
harvested from the blood of an E. equi-infected
horse and E. phagocytophila-infected sheep dem-
onstrated antibodies in 9 of the 10 survivors (7).
The illness was characterized by chills, fever, my-
algias, and headache; some patients also had
nausea, confusion, cough, and arthralgias. Labo-
ratory data included leukopenia in 50%, neu-
tropenia in 17%, lymphopenia in 17%, anemia in
50%, thrombocytopenia in 92%, and elevated
aspartate aminotransferase in 91%. Patients were
predominantly older men (mean age, 68 years).
Clinical history showed strong association with
tick bite preceding the onset of illness.
Current Status of Human Granulocytic Ehrlichia
and Human Granulocytic Ehrlichiosis
Microbiology of Human Granulocytic Ehrlichia and
E. equi
Evidence is accumulating to support the prem-
ise that a single Ehrlichia species is the etiologic
agent of a granulocytotropic ehrlichiosis of hu-
mans, horses, and dogs. The DNA sequences of the
16S rDNA from the peripheral blood of naturally
infected horses and dogs in Sweden, dogs in Min-
nesota and Wisconsin, and horses in Connecticut
are identical with the HGE and differ slightly from
the published 16S rDNA sequence for E. equi
(2,54,55, and J. E. Madigan, J. E. Barlough, J. S.
Dumler, N. S. Schankman, E. DeRock, unpub-
lished observations). Moreover, when infected hu-
man blood from HGE patients is injected into
horses, HGE develops, can be serially transmitted
to other horses, and induces protection against
subsequent  E. equi challenge (56). Also, naturally
occurring canine E. equi infections have been
transmitted to horses that had developed equine
granulocytic ehrlichiosis, and E. equi has been
transmitted experimentally by injecting equine
blood into susceptible dogs (57,58). Reproducible,
continuous in vitro cultivation of all species of
granulocytotropic ehrlichiae, including E. ewingii
and E. equi, is an achievable goal.
E. equi antigens harvested from the blood of
horses with high levels of parasitemia have been
examined for reactivity with convalescent-phase
human (HGE), equine (E. equi), canine (E. equi)
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immunoblotting (59). The antigens judged most
specific for E. equi were the 100-, 44-, 42-, and 25
kDa-bands. The most specific antigen, the 44-kDa
band, was strongly reactive with the convalescent-
phase human, equine, canine, and bovine sera,
suggesting a specific antigenic relationship among
these organisms from different animals and geo-
graphic origins. On the other hand, bio-
logic studies of E. phagocytophila in Finland
have shown apparent strain differences in viru-
lence and lack of immunity to heterologous chal-
lenge (60). The molecular basis for these
differences and the actual taxonomic re-
lationships of HGE, E. equi, and E. phagocy-
tophila remain to be determined.
Clinical Manifestations
A study of 41 cases of laboratory-confirmed
human granulocytic ehrlichiosis from Minnesota
and Wisconsin showed male predominance (78%),
a median age of 59 years (range 6 to 91 years),
median incubation period of 8 days, median period
of fever and other symptoms before initiation of
effective 5-day treatment, and year-round occur-
rence with a peak in June and July (61). Clinical
manifestations included fever (100%), chills
(98%), malaise (98%), myalgias (98%), headaches
(85%), nausea (39%), vomiting (34%), cough (29%),
confusion (17%), and rarely rash (2%). Four pa-
tients had pulmonary infiltrates visible on
roentgenograms. The severity of illness is re-
flected in the rates of hospitalization (56%), admis-
sion to an intensive care unit (7%), and death (5%).
The course of illness in patients who were not
treated and yet survived included a 10-day febrile
course in a child and 3- to 11-week remittent
febrile course in adults (61).
Diagnosis and Treatment
A clinical diagnosis of human granulocytic ehr-
lichiosis should be considered in patients exposed
to an Ixodes scapularis (dammini), I. pacificus or
I. ricinus tick-infested environment who have a
flulike febrile illness. Careful examination of a
peripheral blood smear may show neutrophils
that contain cytoplasmic vacuoles filled with ehr-
lichiae. Two different sets of PCR primers based
upon the 16S rDNA sequence of HGE have been
designed to amplify, detect, and identify HGE in
the patient’s blood during the acute stage of illness
(2,62). Continued improvements in the technology
are expected to yield highly sensitive and specific
results in any well-managed clinical molecular
diagnostics laboratory. Serologic diagnosis by IFA
employing E. equi-infected neutrophils harvested
from the blood of infected horses detects antibod-
ies at a diagnostic titer of 80 or greater in the
convalescent-phase sera of 100% of patients, but
antibodies are usually not present in sera collected
early in the illness.
Among 34 patients treated with doxycycline,
97% defervesced within 2 days. One patient who
had not been treated with doxycycline had E. equi
detectable by PCR in the blood 28 days after onset
of symptoms.
Pathology, Pathogenesis, and Immunity
Following presumed injection of HGE into the
patient’s skin by the bite of Ixodes ssp. ticks,
virtually none of the subsequent events are
known. It is suspected that HGE infects a myeloid
precursor in the bone marrow rather than mature
neutrophils. Bone marrow examinations demon-
strated hypercellularity in two patients and nor-
mocellular marrow in another patient. Autopsies
of three patients who died of HGE showed oppor-
tunistic fungal pneumonia caused by a different
agent (Aspergillus fumigatus, Cryptococcus neo-
formans, and Candida albicans) in each patient,
suggesting altered host defenses (7,63). One of the
patients who died had severe herpes esophagitis.
Co-infection with HGE and B. burgdorferi is sus-
pected to result in more severe disease. Examples
from veterinary research indicating that E. phago-
cytophila and E. equi suppress the host defenses
include opportunistic viral and fungal infections,
decreased neutrophil adherence, emigration,
phagocytosis, and bacterial killing, decreased pro-
duction of antibodies, and decreased lymphocyte
mitogenesis (64,65). The mechanisms by which
ehrlichiae impair the host phagocytic and immune
responses are not known.
Epidemiology and Ecology
Human granulocytic ehrlichiosis has been diag-
nosed in patients in Minnesota, Wisconsin, Mas-
sachusetts, Connecticut, New York, Rhode Island,
Pennsylvania, Maryland, Florida, Arkansas, and
California (7,63,66,67). Serologic evidence sug-
gests that HGE or an antigenically related organ-
ism has also infected patients with Lyme
borreliosis in Switzerland (68). An organism
apparently identical to HGE is present in Sweden
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the vector of Lyme borreliosis in northern Califor-
nia, transmits E. equi to horses (69). Ten percent
of  I. scapularis (dammini) ticks collected from
vegetation in northwestern Wisconsin  in  1982
and 1991 were infected with HGE, including two
specimens containing both HGE and Borrelia
burgdorferi. An engorged I. scapularis (dammini)
tick was removed from a patient with human
granulocytic ehrlichiosis in the same geographic
area. PCR showed that the tick’s salivary glands
contained DNA of  HGE (62). Similarly, PCR-am-
plified HGE DNA was detected in 50% of I. scapu-
laris (dammini) ticks collected in Connecticut; no
E. chaffeensis was detected in these ticks (70).
Although the demonstration by PCR that blood
from a high proportion of deer in a study in Wis-
consin contained HGE suggests that deer might
be an important reservoir, the possibility of a
rodent reservoir should also be investigated. In-
deed, the illustrations in a 1938 Tyzzer article
suggest that Microtus pennsylvanicus and
Peromyscus leucopus are naturally infected with a
granulocytotropic ehrlichia (71).
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